KYTX — Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ. It is led by Warner Biddle, based in 5980 Horton Street, Emeryville, CA, United States, 94608, with about 129 employees. Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Net income was -$36.8M. KYTX currently screens at market cap $488.8M.

Use this KYTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KYTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KYTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Kyverna Therapeutics, Inc. Common Stock even when a live quote feed is slow.